First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study

Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles